Porcel (2012) Clinical Implications of Pleural Effusions in Ovarian Cancer
Porcel (2012) Clinical Implications of Pleural Effusions in Ovarian Cancer
Porcel (2012) Clinical Implications of Pleural Effusions in Ovarian Cancer
INVITED REVIEW
1
Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Biomedical
Research Institute of Lleida, Lleida, Spain, 2Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami,
Florida, and 3Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center,
New York, USA
PROGNOSIS
abdominal cytoreduction may be negated if VATS intrathoracic washing cytology for stage IIIc ovarian cancer with
identifies unresectable pleural disease. In this sce- diaphragmatic metastases. Int. J. Gynecol. Cancer 2009; 19:
nario, patients should be considered for neoadjuvant 300–3.
19 Fleury AC, Kushnir CL, Giuntoli IIRL et al. Upper abdominal
chemotherapy. Currently, it is not clear if bulky
cytoreduction and thoracoscopy for advanced epithelial ovarian
intrathoracic disease may be present in OC patients cancer: unanswered questions and the impact on treatment.
with small pleural effusions and if VATS could have a BJOG 2012; 119: 202–6.
role in this particular subgroup. A treatment algo- 20 Porcel J, Rodríguez-Panadero F. Malignant effusions. In: Maskell
rithm for patients with malignant pleural effusions N, Millar A (eds) Oxford Desk Reference: Respiratory Medicine.
due to OC is suggested in Figure 4. Oxford University Press, Oxford, 2009; 342–5.
21 Rodríguez-Panadero F. Medical thoracoscopy. Respiration 2008;
76: 363–72.
ACKNOWLEDGEMENT 22 Ganjei-Azar P, Jordà M, Krishan A (eds). Effusion Cytology. A Prac-
tical Guide to Cancer Diagnosis. Demos Medical, New York, 2011.
23 Westfall DE, Fan X, Marchevsky AN. Evidence-based guidelines
Dr Silvia Bielsa’s assistance in the preparation of the
to optimize the selection of antibody panels in cytopathology:
manuscript was greatly appreciated. pleural effusions with malignant epithelioid cells. Diagn. Cyto-
pathol. 2010; 38: 9–14.
24 Díaz JP, Abu-Rustum NR, Sonoda Y et al. Video-assisted thoracic
REFERENCES surgery (VATS) evaluation of pleural effusions in patients with
newly diagnosed advanced ovarian carcinoma can influence the
1 Jemal A, Bray F, Center MM et al. Global cancer statistics. primary management choice for these patients. Gynecol. Oncol.
CA Cancer J. Clin. 2011; 61: 69–90. 2010; 116: 483–8.
2 Jelovac D, Armstrong DK. Recent progress in the diagnosis and 25 Kim KW, Choi HJ, Kang S et al. The utility of multi-detector com-
treatment of ovarian cancer. CA Cancer J. Clin. 2011; 61: 183–203. puted tomography in the diagnosis of malignant pleural effusion
3 Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 in the patients with ovarian cancer. Eur. J. Radiol. 2010; 75: 230–5.
mutations among 1342 unselected patients with invasive ovarian 26 Mironov O, Sala E, Mironov S et al. Thoracic metastases in
cancer. Gynecol. Oncol. 2011; 121: 353–7. advanced ovarian cancer: comparison between computed
4 Berek JS, Chalas E, Edelson M et al. Prophylactic and risk- tomography and video-assisted thoracic surgery. J. Gynecol.
reducing bilateral salpingo-oophorectomy: recommendations Oncol. 2011; 22: 260–8.
based on risk of ovarian cancer. Obstet. Gynecol. 2010; 116: 733– 27 Cohen-Mouly S, Badia A, Bats AS et al. Role of video-assisted
43. thoracoscopy in patients with ovarian cancer and pleural effu-
5 Tarn AC, Lapworth R. Biochemical analysis of ascitic (peritoneal) sion. Int. J. Gynecol. Cancer 2009; 19: 1662–5.
fluid: what should we measure? Ann. Clin. Biochem. 2010; 47: 28 Juretzka MM, Abu-Rustum NR, Sonoda Y et al. The impact of
397–407. video-assisted thoracic surgery (VATS) in patients with sus-
6 Bielsa S, Porcel JM, Castellote J et al. Solving the Light’s criteria pected advanced ovarian malignancies and pleural effusions.
misclassification rate of cardiac and hepatic transudates. Gynecol. Oncol. 2007; 104: 670–4.
Respirology 2012; 17: 721–6. 29 Morgan RJ, Alvarez RD, Armstrong DK et al. Epithelial ovarian
7 Moore RG, Maclaughlan S. Current clinical use of biomarkers for cancer. J. Natl Compr. Canc. Netw. 2011; 9: 82–113.
epithelial ovarian cancer. Curr. Opin. Oncol. 2010; 22: 492–7. 30 Vergote I, Tropé CG, Amant F et al. Neodjuvant chemotherapy or
8 Escudero JM, Auge JM, Filella X et al. Comparison of serum primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med.
human epididymis protein 4 with cancer antigen 125 as a tumor 2010; 363: 943–53.
marker in patients with malignant and nonmalignant diseases. 31 Amstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin
Clin. Chem. 2011; 57: 1534–44. and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354: 34–43.
9 Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian 32 Chi DS, Eisenhauer EL, Zivanovic O et al. Improved progression-
malignancy. Gynecol. Oncol. 2002; 87: 77–83. free and overall survival in advanced ovarian cancer as a result of
10 Hernández P, Bielsa S, Pardina M et al. Meig’s syndrome. Int. a change in surgical paradigm. Gynecol. Oncol. 2009; 114: 26–31.
Pleural Newsl. 2011; 9: 10. 33 Rauh-Hain JA, Rodriguez N, Growdon WB et al. Primary debulk-
11 Maeda H, Okabayashi T, Hanazaki K et al. Clinical experience of ing surgery versus neodjuvant chemotherapy in stage IV ovarian
pseudo-Meig’s syndrome due to colon cancer. World J. Gastro- carcinoma. Ann. Surg. Oncol. 2012; 19: 959–65.
enterol. 2011; 17: 3263–6. 34 Gerestein CG, Eijkemans MJ, Bakker J et al. Nomogram for sub-
12 Cetin B, Aslan S, Akinci M et al. A long survival case of pseudo- optimal cytoreduction at primary surgery for advanced stage
Meig’s syndrome caused by Krukenberg tumor of the stomach. ovarian cancer. Anticancer Res. 2011; 31: 4043–9.
Jpn J. Clin. Oncol. 2005; 35: 221–3. 35 Aletti GD, Eisenhauer EL, Santillan A et al. Identification of
13 Kawakubo N, Okido M, Tanaka R et al. Pseudo-Meig’s syndrome patient groups at higher risk from traditional approach to
associated with breast cancer metastasis to both ovaries: report ovarian cancer treatment. Gynecol. Oncol. 2011; 120: 23–8.
of a case. Surg. Today 2010; 40: 1148–51. 36 Elattar A, Bryant A, Winter-Roach BA et al. Optimal primary sur-
14 Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: gical treatment for advanced epithelial ovarian cancer. Cochrane
an overview. Arch. Pathol. Lab. Med. 2006; 130: 1725–30. Database Syst. Rev. 2011; (8): CD007565.
15 Cellerin L, Marcq M, Sagan C et al. Pleurésies malignes révéla- 37 Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of
trices d’un cancer: comparaison des etiologies avec les pleuré- maximal cytoreductive surgery for advanced ovarian carcinoma
sies métastatiques d’un cancer connu. Rev. Mal. Respir. 2008; 25: during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20:
1104–9. 1248–59.
16 Wimberger P, Wehling M, Lehmann N et al. Influence of residual 38 Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for
tumor on outcome in ovarian cancer patients with FIGO stage IV advanced ovarian cancer: Quo Vadis? Oncology (Williston Park)
disease. Ann. Surg. Oncol. 2010; 17: 1642–8. 2011; 25: 928–34.
17 Bristow R, Amstrong D (eds). Ovarian Cancer. Saunders Elsevier, 39 Eisenhauer EL, D’Angelica MI, Abu-Rustum NR et al. Incidence
Philadelphia, PA, 2010. and management of pleural effusions after diaphragm peri-
18 Terauchi F, Kobayashi I, Nagashima T et al. Pilot study on trans- tonectomy or resection for advanced mullerian cancer. Gynecol.
diaphragmatic thoracoscopic assisted pleural biopsy and Oncol. 2006; 103: 871–7.